Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 6
2003 5
2004 5
2005 4
2006 7
2007 5
2008 8
2009 11
2010 16
2011 16
2012 12
2013 15
2014 17
2015 14
2016 21
2017 32
2018 26
2019 26
2020 41
2021 28
Text availability
Article attribute
Article type
Publication date

Search Results

271 results
Results by year
Filters applied: . Clear all
Page 1
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suárez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J; DANUBE study investigators. Powles T, et al. Lancet Oncol. 2020 Dec;21(12):1574-1588. doi: 10.1016/S1470-2045(20)30541-6. Epub 2020 Sep 21. Lancet Oncol. 2020. PMID: 32971005 Clinical Trial.
Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients.
Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Mizowaki T, Kamoto T, Kojima T, Kitamura H, Sugimoto M, Nishiyama H, Eto M; Japanese Urological Oncology Group (JUOG). Shiota M, et al. Among authors: hashimoto y. Cancer Sci. 2021 Apr;112(4):1524-1533. doi: 10.1111/cas.14722. Epub 2021 Feb 13. Cancer Sci. 2021. PMID: 33159829 Free PMC article.
Geriatric 8 screening of frailty in patients with prostate cancer.
Momota M, Hatakeyama S, Soma O, Tanaka T, Hamano I, Fujita N, Okamoto T, Yoneyama T, Yamamoto H, Imai A, Yoshikawa K, Yoneyama T, Hashimoto Y, Ohyama C. Momota M, et al. Among authors: hashimoto y. Int J Urol. 2020 Aug;27(8):642-648. doi: 10.1111/iju.14256. Epub 2020 Jun 4. Int J Urol. 2020. PMID: 32500621
Relationship between frailty and lower urinary tract symptoms among community-dwelling adults.
Soma O, Hatakeyama S, Imai A, Matsumoto T, Hamano I, Fujita N, Iwamura H, Okamoto T, Yamamoto H, Tobisawa Y, Yoneyama T, Yoneyama T, Hashimoto Y, Nakaji S, Ohyama C. Soma O, et al. Among authors: hashimoto y. Low Urin Tract Symptoms. 2020 May;12(2):128-136. doi: 10.1111/luts.12292. Epub 2019 Oct 23. Low Urin Tract Symptoms. 2020. PMID: 31642610
Utility of plasma cell-free DNA in metastatic castration-resistant prostate cancer.
Hamano I, Hatakeyama S, Hamaya T, Togashi K, Okamoto T, Yamamoto H, Yoneyama T, Yoneyama T, Hashimoto Y, Ohyama C. Hamano I, et al. Among authors: hashimoto y. IJU Case Rep. 2020 Jun 7;3(4):141-144. doi: 10.1002/iju5.12172. eCollection 2020 Jul. IJU Case Rep. 2020. PMID: 33392474 Free PMC article.
271 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page